5-FU bolus removal from chemotherapy regimens for advanced gastrointestinal cancers does not affect patient survival, study finds.
A study in the Journal of the National Comprehensive Cancer Network reveals that removing the bolus 5-fluorouracil (5-FU) from chemotherapy regimens for advanced gastrointestinal cancers does not compromise patient survival. Analyzing data from 11,765 patients, researchers found that 13.7% of those without the bolus experienced fewer side effects, such as neutropenia and thrombocytopenia, making treatment more tolerable and potentially reducing healthcare costs.
September 05, 2024
6 Articles